

Date: 21st March, 2018

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Tower, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir/Madam,

Sub: US FDA Inspection at Alembic Pharmaceuticals Formulation Facility at Panelav

We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals Formulation Facility located at Panelav from 12th March, 2018 to 20th March, 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations.

None of the observations are related to data integrity or repetitive in nature.

The Company is preparing the response to the observations, which will be submitted to the US FDA shortly.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director – Finance & CFO

Date: 21st March, 2018

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir/Madam,

Sub: US FDA Inspection at Alembic Pharmaceuticals Formulation Facility at Panelav

We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals Formulation Facility located at Panelav from 12th March, 2018 to 20th March, 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations.

None of the observations are related to data integrity or repetitive in nature.

The Company is preparing the response to the observations, which will be submitted to the US FDA shortly.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director – Finance & CFO